Aura Biosciences: A Strong Buy on Promising Clinical Trials and Market Potential

In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on Aura Biosciences Inc (AURA – Research Report), with a price target of $21.00.

Julian Harrison has given his Buy rating due to a combination of factors related to Aura Biosciences’ clinical developments and market potential. The progress in the Phase 3 CoMpass trial for bel-sar in treating primary choroidal melanoma is on track, with additional trial sites activated and enrollment proceeding as planned. The FDA’s Special Protocol Assessment for the trial underscores its solid design and potential to support a Biologics License Application. Furthermore, management’s reaffirmation of the upcoming Phase 2 trial for bel-sar in choroidal metastasis and the presentation of promising preclinical data in ocular surface cancers suggest multiple avenues for the product’s clinical success.
Additionally, Harrison’s optimism is bolstered by the expansion of the Phase 1 bladder cancer trial to include a broader patient population, with early data showing a complete response in a patient from the light-activated cohort. The company’s financial position, with sufficient cash to fund operations into the second half of 2026, provides a stable foundation for continued development. The potential for bel-sar to become the first approved treatment for primary choroidal melanoma, addressing a significant unmet medical need with a high probability for early intervention, contributes to the favorable outlook for Aura Biosciences’ stock and justifies the Buy rating.

In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Aura Biosciences Inc (AURA) Company Description:

Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity.